Skip to main content

Table 1 Patient characteristics

From: Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study

 

Total (n = 94)

CC (n = 46)

CP (n = 48)

Age, years

   

Median (range)

63 (34–82)

62 (46–76)

63 (34–82)

Gender

   

Male

92

45

47

Female

2

1

1

Smoking history

   

Never

7

5

2

Current or former

85

39

46

Prior therapy

   

Surgery

31

15

16

Radiotherapy

20

10

10

Chemotherapy (adjuvant or neoadjuvant)

19

9

10

Initial disease status

   

Initial advanced state

59

29

30

Recurred state

35

17

18

Locoregional disease

4

3

1

Distant metastasis

90

43

47

No. of metastatic sites

   

One

45

24

21

Two or more

49

22

27

Metastatic sites

   

Neck, supraclavicular LN

51

24

27

Abdominal LN

42

23

19

Lung

30

10

20

Bone

17

8

9

Liver

12

6

6

  1. CC capecitabine plus cisplatin, CP, capecitabine plus paclitaxel, ECOG, Eastern Cooperative Oncology Group, LN, lymph nodes